Sangamo Therapeutics (NASDAQ:SGMO) Coverage Initiated by Analysts at Wall Street Zen

Wall Street Zen assumed coverage on shares of Sangamo Therapeutics (NASDAQ:SGMO) in a research report report published on Thursday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

Other analysts have also issued reports about the company. Barclays reduced their target price on Sangamo Therapeutics from $9.00 to $5.00 and set an “overweight” rating on the stock in a report on Wednesday, May 14th. HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Sangamo Therapeutics in a research note on Monday, April 7th. Royal Bank of Canada reissued a “sector perform” rating and issued a $2.00 price objective on shares of Sangamo Therapeutics in a research note on Tuesday, March 18th. Finally, Truist Financial lowered their target price on Sangamo Therapeutics from $7.00 to $5.00 and set a “buy” rating for the company in a research note on Thursday, January 23rd. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $4.50.

Sangamo Therapeutics Stock Performance

SGMO stock opened at $0.47 on Thursday. Sangamo Therapeutics has a 52 week low of $0.30 and a 52 week high of $3.18. The company has a market capitalization of $110.36 million, a PE ratio of -0.63 and a beta of 1.46. The company’s 50-day simple moving average is $0.69 and its 200 day simple moving average is $1.26.

Sangamo Therapeutics (NASDAQ:SGMO) last issued its quarterly earnings results on Monday, May 12th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.03). The company had revenue of $6.44 million during the quarter, compared to the consensus estimate of $7.90 million. Sangamo Therapeutics had a negative net margin of 257.87% and a negative return on equity of 264.16%. On average, analysts forecast that Sangamo Therapeutics will post -0.46 EPS for the current year.

Institutional Trading of Sangamo Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. E Fund Management Co. Ltd. bought a new position in shares of Sangamo Therapeutics during the 4th quarter worth approximately $25,000. JPMorgan Chase & Co. increased its position in Sangamo Therapeutics by 679.5% in the fourth quarter. JPMorgan Chase & Co. now owns 25,000 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 21,793 shares during the last quarter. PNC Financial Services Group Inc. raised its stake in shares of Sangamo Therapeutics by 2,319.1% in the fourth quarter. PNC Financial Services Group Inc. now owns 26,078 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 25,000 shares during the period. SBI Securities Co. Ltd. purchased a new position in shares of Sangamo Therapeutics during the 4th quarter valued at $28,000. Finally, Captrust Financial Advisors purchased a new position in shares of Sangamo Therapeutics during the 4th quarter valued at $30,000. 56.93% of the stock is owned by hedge funds and other institutional investors.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.